

CORRECTION

Open Access

Correction to: The design and development of covalent protein-protein interaction inhibitors for cancer treatment



Sha-Sha Cheng^{1†}, Guan-Jun Yang^{1†}, Wanhe Wang², Chung-Hang Leung^{1*} and Dik-Lung Ma^{2*}

Correction to: J Hematol Oncol 13, 26 (2020)
<https://doi.org/10.1186/s13045-020-00850-0>

The original article [1] contains an omission in the legend of Fig. 2 whereby inadequate credit was given to the authors of the original print of Fig. 2 which was reproduced from the original article published in *Medicinal Research Reviews* [2].

The correct version of Fig. 2's legend with appropriate citation can be viewed ahead alongside its respective figure.

The original article can be found online at <https://doi.org/10.1186/s13045-020-00850-0>.

* Correspondence: duncanleung@um.edu.mo; edmondma@hkbu.edu.hk

†Sha-Sha Cheng and Guan-Jun Yang contributed equally to this work.

¹State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China

²Department of Chemistry, Hong Kong Baptist University, Hong Kong 999077, China



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 2 The crystal structure of three different classes of PPIs [2]. A) Linear sequences comprise primary peptide epitopes (e.g. LM of DNA polymerase III bound to the binding pocket of the SC (PDB: 3D1F)); B) the secondary structure of epitopes binds as a single unit. e.g. an α -helix (NusB-NusE PPI (PDB: 3R2C)); and C) in tertiary structural epitopes, the binding interface is not continuous and both sides of PPI interface are needed (e.g. IL-2/IL-2Ra PPI (PDB 1Z92))

Published online: 24 July 2020

References

1. Cheng S-S, et al. The design and development of covalent protein-protein interaction inhibitors for cancer treatment. *J Hematol Oncol.* 2020;13:26 <https://doi.org/10.1186/s13045-020-00850-0>.
2. Cossar PJ, Lewis PJ, McCluskey A. Protein-protein interactions as antibiotic targets: a medicinal chemistry perspective. *Med Res Rev.* 2018;40:2 <https://doi.org/10.1002/med.21519>.